When a clinical trial at a hospital in Lebanon concluded, eight pediatric patients were receiving treatment through the program. Only two of those patients lived in Lebanon. For the remaining six children, continuing care suddenly became far more complicated.

This recap captures the key themes emerging from GCSG conversations, including the evolution of pharmacy manuals from static documentation into dynamic tools that support execution and compliance, the growing prioritization of patient-centricity as an operational imperative, and the increasing importance of strategic sponsor-vendor partnerships in areas such as comparator sourcing and clinical supply management.

This recap captures the key themes emerging from CTSS discussions, including the increasing adoption of AI-driven forecasting and planning tools, the need for greater ecosystem connectivity between sponsors, CROs, and vendors, and the growing importance of end-to-end visibility across clinical supply operations. Industry leaders consistently emphasized that the next generation of CTS will depend on unified, data-driven approaches that reduce complexity, anticipate disruptions earlier, and support more agile decision-making.

This recap captures the key themes emerging from the discussions at CHPI Japan, including the operational challenges and opportunities created by evolving R&D pipelines, increasingly sophisticated therapies, and the growing need for scalable global access models.

Swiss Biotech Day 2026 once again highlighted why Basel remains a key hub for global life sciences innovation. Bringing together more than 3,000 biotech and pharma leaders from nearly 50 countries, the event sparked important conversations around collaboration, clinical development, global access, and operational execution across the industry.

This event recap highlights how evolving partnership models, AI-driven insights, and emerging therapeutic focus areas are shaping faster, more strategic biopharma decision-making.

This event recap explores the realities behind comparator strategy and why early, deliberate planning is critical to avoiding costly delays.

This event recap explores common misconceptions around for-charge Expanded Access Programs (EAPs), highlighting key considerations for compliant, scalable global access strategies.

Tanner’s Managed Access Program (MAP) division specializes in increasing access to life-saving treatments for patients who would otherwise be unable to access them, either via pre-approval access programs or global donation programs. TannerMAP also develops and delivers access programs for specific medicines from manufacturer partners.

Managing clinical trial supply across multiple regions is becoming more complex, with tighter timelines and increasing regulatory demands. This article explores how to source and deliver trial materials globally while keeping studies on track.

This article explores how climate change is impacting the pharmaceutical supply chain, highlighting challenges in logistics, rising demand, and the need for more sustainable and resilient approaches.

Mexico’s pharmaceutical market is experiencing strong growth, driven by manufacturing advantages, increasing investment, and evolving regulatory frameworks shaping opportunities in the region.

Brazil’s pharmaceutical market continues to evolve, shaped by regulatory changes, public healthcare investment, and ongoing shifts in policy that may influence future growth and access.

Drug shortages are impacting patients worldwide, driven by global disruptions, with a focus on how supply challenges can be managed to maintain access to essential medicines.

Maintaining access to treatment is a critical challenge for patients worldwide, with a focus on how access programs and global supply networks help ensure continuity of care.

Medical product classification varies across Latin America, with a focus on how regulatory differences impact market access and the importance of local expertise in navigating these complexities.

Pharmaceutical companies are advancing supply chain sustainability, with a focus on reducing carbon emissions, improving logistics efficiency, and adopting more environmentally responsible practices.

In partnership with RARE Revolution, Tanner Pharma Group co-hosted a webinar bringing together stakeholders to discuss early access pathways, including collaboration, communication, real-world data, and patient access.